Allogeneic hematopoietic stem cell transplantation during the normalization stage of COVID-19 management
10.3760/cma.j.cn121090-20240817-00308
- VernacularTitle:新型冠状病毒肺炎疫情防控常态化阶段的异基因造血干细胞移植
- Author:
Qifa LIU
1
;
Ren LIN
1
Author Information
1. 南方医科大学南方医院血液科，南方医科大学血液病研究所，广东省血液系统疾病临床医学研究中心，广州 510515
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2024;45(11):977-981
- CountryChina
- Language:Chinese
-
Abstract:
At present, the world has entered the normalization stage of coronavirus disease 2019 (COVID-19) management. COVID-19 continues to affect patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for a long period. The author discussed the possible effect of COVID-19 on HSCT strategy and prognosis during this period based on literature reports. Transplantation should be deferred until clinical resolution and negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients infected with SARS-CoV-2 before transplantation. Donors infected with SARS-CoV-2 during the stem cell collection may not affect apheresis. Allo-HSCT recipients demonstrated a high rate of severe COVID-19 if COVID-19 occurred at the early stage of transplantation. Severe COVID-19 remains a risk factor for nonrelapse mortality and survival after transplantation. The association between COVID-19 and post-transplantation complications, such as other infections, endothelial injury-related complications, and relapse, needs to be further investigated in large samples.
